A. Rialland

发表

Red blood cells free α‐haemoglobin pool: a biomarker to monitor the β‐thalassemia intermedia variability. The ALPHAPOOL study

V. Baudin-Creuza, F. Galactéros, B. Ghaleh, 2017, British journal of haematology.

Efficacy and tolerance of early administration of tranexamic acid in patients with cirrhosis presenting with acute upper gastrointestinal bleeding: a study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (the EXARHOSE study)

R. Amathieu, E. Audureau, O. Thirion, 2018, BMJ Open.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Enrico Amico, Philippe Allain, Mark Mühlau, 2017, The Lancet. Neurology.

Chronic high dose transdermal nicotine in Parkinson's disease: an open trial

I. Macquin-Mavier, P. Maison, P. Césaro, 2007, European journal of neurology.

Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial

G. Baron, P. Ravaud, D. Loeuille, 2014, Annals of the rheumatic diseases.

Alloimmunisation to Donor Antigens and Immune Rejection Following Foetal Neural Grafts to the Brain in Patients with Huntington's Disease

Anne-Catherine Bachoud-Lévi, Véronique Gaura, Marc Peschanski, 2007, PloS one.

pH as a Biomarker of Neurodegeneration in Huntington's Disease: A Translational Rodent-Human MRS Study

P. Remy, P. Damier, J. Valette, 2012, Journal of Cerebral Blood Flow and Metabolism.

Longitudinal Study of Informed Consent in Innovative Therapy Research: Experience and Provisional Recommendations from a Multicenter Trial of Intracerebral Grafting

J. Démonet, P. Damier, P. Krystkowiak, 2015, PloS one.

COMT Val158Met Polymorphism Modulates Huntington's Disease Progression

Emmanuel Dupoux, R. de Diego-Balaguer, A. Durr, 2016, PloS one.

NMDA receptor gene variations as modifiers in Huntington disease: a replication study

J. Schiefer, R. Barker, R. Reilmann, 2011, PLoS currents.

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study

R. Reilmann, K. Marder, J. Corey-Bloom, 2019, The Lancet Neurology.

A Wake-Up Call for Routine Morbidity and Mortality Review Meeting Procedures as Part of a Quality Governance Programs in Radiation Therapy Departments: Results of the PROUST Survey.

David Azria, M. Bollet, Y. Belkacemi, 2019, Practical radiation oncology.

COMT Val158Met Polymorphism Modulates Huntington's Disease Progression

Emmanuel Dupoux, R. de Diego-Balaguer, A. Durr, 2016, PloS one.

pH as a Biomarker of Neurodegeneration in Huntington's Disease: A Translational Rodent-Human MRS Study

P. Remy, P. Damier, J. Valette, 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.